Cyclin D1 Amplification in Multiple Myeloma Is Associated With Multidrug Resistance Expression

• Published in: Clinical lymphoma, myeloma and leukemia Vol. 14; no. 3; pp. 215 - 222
• Main Authors: Sewify, Eman M, Afifi, Ola A, Mosad, Eman, Zaki, Amen H, El Gammal, Sahar A
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01-06-2014
• Subjects: Aged; ATP-Binding Cassette, Sub-Family B, Member 1 - genetics; ATP-Binding Cassette, Sub-Family B, Member 1 - metabolism; Bone Neoplasms - pathology; Chemoresistance; Cyclin D1 - genetics; Cyclin D1 - metabolism; FISH; Gene Amplification; Hematologic malignancies; Hematology, Oncology and Palliative Medicine; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Middle Aged; Multiple Myeloma - diagnosis; Multiple Myeloma - genetics; Multiple Myeloma - mortality; Neoplasm Staging; Odds Ratio; Overall survival; Prognosis; Immunohistochemistry; FISH; Hematologic malignancies; Overall survival; Chemoresistance
• ISSN: 2152-2650; 2152-2669
• DOI: 10.1016/j.clml.2013.07.008

Micro-Abstract In this study, we evaluated cyclin D1 gene amplification using fluorescence in situ hybridization (FISH) and multidrug resistance (MDR1) protein using immunohistochemistry in bone marrow biopsies of 50 patients with multiple myeloma. Cyclin D1-positive patients had a significantly lower progression-free and overall survival and higher levels of MDR1 compared with cyclin D1-negative patients, suggesting an association between cyclin D1 gene amplification and MDR1 unfavorable prognosis.